Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended letermovir prophylaxis after allogeneic HSCT in CMV-seropositive recipients
2018-001038-17Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus disease (CMV), sponsored by Merck & Co.. Status: unknown.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2018-001038-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001038-17.